| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock | Options Exercise | $93.3K | +15K | +6.25% | $6.22 | 255K | Feb 2, 2023 | Direct | |
| transaction | PLRX | Common Stock | Sale | -$457K | -13.4K | -5.25% | $34.13 | 242K | Feb 2, 2023 | Direct | F1, F2 |
| transaction | PLRX | Common Stock | Sale | -$56.1K | -1.61K | -0.66% | $34.96 | 240K | Feb 2, 2023 | Direct | F1, F3 |
| transaction | PLRX | Common Stock | Options Exercise | $93.3K | +15K | +6.25% | $6.22 | 255K | Feb 3, 2023 | Direct | |
| transaction | PLRX | Common Stock | Sale | -$325K | -9.74K | -3.82% | $33.36 | 245K | Feb 3, 2023 | Direct | F1, F4 |
| transaction | PLRX | Common Stock | Sale | -$179K | -5.26K | -2.14% | $34.08 | 240K | Feb 3, 2023 | Direct | F1, F5 |
| holding | PLRX | Common Stock | 409K | Feb 2, 2023 | See footnote | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Stock Option (right to buy) | Options Exercise | $0 | -15K | -4.2% | $0.00 | 342K | Feb 2, 2023 | Common Stock | 15K | $6.22 | Direct | F7 |
| transaction | PLRX | Stock Option (right to buy) | Options Exercise | $0 | -15K | -4.38% | $0.00 | 327K | Feb 3, 2023 | Common Stock | 15K | $6.22 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.48, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. |
| F4 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.83, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. |
| F5 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4. |
| F6 | Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| F7 | 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. |